Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI–Treated Non–Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy-Reference-Cited by-同舟云学术

Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI–Treated Non–Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy

Published:2019-05 Issue:3 Volume:20 Page:e229-e232
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Ding Meijuan,Deng Lili,Yu Ruoying,Lu Dan,Bai Yun,Wu Xue,Shao Yang W.,Yang Yu

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. IASLC statement paper: liquid biopsy for advanced non–small-cell lung cancer (NSCLC);Rolfo;J Thorac Oncol,2018

2. ALK inhibitors in non–small-cell lung cancer: the latest evidence and developments;Sullivan;Ther Adv Med Oncol,2016

3. Enteral administration of TKIs: report of a response to ceritinib in an ALK-positive NSCLC patient and literature review;Facchinetti;Curr Drug Targets,2018

4. The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis;Fan;Onco Targets Ther,2018

5. Brigatinib Effective in ALK+ NSCLC;Cancer Discov,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy;Methods in Molecular Biology;2023

2. Lorlatinib as a treatment for ALK-positive lung cancer;Future Oncology;2022-08

3. Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report;OncoTargets and Therapy;2021-08

4. Brigatinib/crizotinib/lorlatinib;Reactions Weekly;2020-05

5. Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers;Journal of Clinical Medicine;2019-07-09